Basit öğe kaydını göster

dc.contributor.authorKalincik, T.
dc.contributor.authorSobisek, L.
dc.contributor.authorJokubaitis, V.
dc.contributor.authorSpelman, T.
dc.contributor.authorHorakova, D.
dc.contributor.authorHavrdova, E.
dc.contributor.authorGranella, F.
dc.date.accessioned2020-06-21T13:32:22Z
dc.date.available2020-06-21T13:32:22Z
dc.date.issued2016
dc.identifier.issn1352-4585
dc.identifier.issn1477-0970
dc.identifier.urihttps://hdl.handle.net/20.500.12712/13185
dc.description32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) -- SEP 14-17, 2016 -- London, ENGLANDen_US
dc.descriptionHavrdova, Eva Kubala/0000-0002-9543-4359; McCombe, Pamela/0000-0003-2704-8517; Sobisek, Lukas/0000-0001-8071-2005; Oreja-Guevara, Celia/0000-0002-9221-5716; Slee, Mark/0000-0003-4323-2453; Lugaresi, Alessandra/0000-0003-2902-5589;en_US
dc.descriptionWOS: 000383267201468en_US
dc.description.abstracten_US
dc.description.sponsorshipEuropean Comm Treatment & Res Multiple Sclerosisen_US
dc.description.sponsorshipBiogenBiogen; NovartisNovartis; Merck SeronoMerck SeronoMerck & Company; Teva; Charles University in Prague [PRVOUK-P26/LF1/4]; Charles University in Prague (Czech Ministry of Health) [NT13237-4/2012]; GenzymeGenzyme Corporation; BayerBayer AG; MerckMerck & Company; SanofiSanofi-Aventis; Fondazione Italiana Sclerosi Multipla (FISM)Fondazione Italiana Sclerosi Multipla (FISM); Teva Canada Innovation; Genzyme SanofiGenzyme Corporation; EMD SeronoMerck Serono; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); EMDSeronoMerck Serono; TEVA Neuroscience; CIHRCanadian Institutes of Health Research (CIHR); MS Society of Canada; Merck-SeronoMerck SeronoMerck & Company; Mitsubishi; ONO Pharmaceuticals; UCBUCB Pharma SA; LundbeckLundbeck Corporation; Bayer ScheringBayer AGen_US
dc.description.sponsorshipTomas Kalincik served on scientific advisory boards for Roche, Genzyme, Novartis, Merck and Biogen, has received conference travel support and/or speaker honoraria from WebMD Global, Novartis, Biogen, Sanofi, Genzyme, Teva, BioCSL and Merck and has received research support from Biogen.; Lukas Sobisek received research fellowship from Novartis and long term institutional support for research activities from the Faculty of Informatics and Statistics, University of Economics, Prague.; Dana Horakova received speaker honoraria and consulting fees from Biogen, Merck Serono, Teva and Novartis, as well as support for research activities from Biogen and research grants from Charles University in Prague (PRVOUK-P26/LF1/4 and Czech Ministry of Health (NT13237-4/2012).; Eva Havrdova received speaker honoraria and consultant fees from Biogen, Merck Serono, Novartis, Genzyme and Teva, as well as support for research activities from Biogen, Merck Serono and research grants from Charles University in Prague (PRVOUK-P26/LF1/4 and Czech Ministry of Health (NT13237-4/2012).; Alessandra Lugaresi is a Bayer, Biogen, Genzyme, Merck Advisory Board Member. She received travel grants and honoraria from Bayer, Biogen, Merck, Novartis, Sanofi, Teva and Fondazione Italiana Sclerosi Multipla (FISM). Her institution received research grants from Bayer, Biogen, Merck, Novartis, Sanofi, Teva and Fondazione Italiana Sclerosi Multipla (FISM). Alexandre Prat did not declare any competing interests.; Marc Girard received consulting fees from Teva Canada Innovation, Biogen, Novartis and Genzyme Sanofi; lecture payments from Teva Canada Innovation, Novartis and EMD Serono. He has also received a research grant from Canadian Institutes of Health Research.; Pierre Duquette served on editorial boards and has been supported to attend meetings by EMDSerono, Biogen, Novartis, Genzyme, and TEVA Neuroscience. He holds grants from the CIHR and the MS Society of Canada and has received funding for investigator-initiated trials from Biogen, Novartis, and Genzyme.; Raymond Hupperts received honoraria as consultant on scientific advisory boards from Merck-Serono, Biogen, Genzyme-Sanofi and Teva, research funding from Merck-Serono and Biogen, and speaker honoraria from Sanofi-Genzyme and Novartis.; Francois Grand'Maison received honoraria or research funding from Biogen, Genzyme, Novartis, Teva Neurosciences, Mitsubishi and ONO Pharmaceuticals.; Eugenio Pucci served on scientific advisory boards for Merck Serono, Genzyme and Biogen; he has received honoraria and travel grants from Sanofi Aventis, UCB, Lundbeck, Novartis, Bayer Schering, Biogen, Merck Serono, Genzyme and Teva; he has received travel grants and equipment from "Associazione Marchigiana Sclerosi Multipla e altre malattie neurologiche".en_US
dc.language.isoengen_US
dc.publisherSage Publications Ltden_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleIndividual response to disease modifying therapies: a global observational cohort studyen_US
dc.typeconferenceObjecten_US
dc.contributor.departmentOMÜen_US
dc.identifier.volume22en_US
dc.identifier.startpage358en_US
dc.identifier.endpage360en_US
dc.relation.journalMultiple Sclerosis Journalen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster